Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: In the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial, Dr Stevenson and colleagues1 showed that the addition of the pulmonary artery catheter (PAC) to “clinical assessment alone” in the treatment of decompensated heart failure did not affect overall mortality and hospitalization. This finding of no effect could have been explained in part by use of continuous central venous pressure (CVP) monitoring via indwelling central venous lines other than PACs among participants randomized to receive therapy guided by clinical assessment alone. In the absence of pulmonary hypertension or profound right ventricular dysfunction, CVP provides a reasonable estimation of left ventricular filling characteristics.2,3 Serial measurements of CVP may provide useful information about response to treatment of volume overload.4
Won C, Kuschner WG. Pulmonary Artery Catheter Effectiveness in Congestive Heart Failure. JAMA. 2006;295(10):1121–1122. doi:10.1001/jama.295.10.1121-a
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: